S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
OTCMKTS:ATRX

Adhera Therapeutics (ATRX) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free ATRX Stock Alerts
$0.0060
0.00 (0.00%)
(As of 04/18/2024 ET)
Compare
Today's Range
$0.0060
▼
$0.0071
50-Day Range
$0.0060
▼
$0.0168
52-Week Range
$0.01
▼
$0.60
Volume
302 shs
Average Volume
118,907 shs
Market Capitalization
$69,780.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsFinancialsSEC FilingsShort Interest
ATRX stock logo

About Adhera Therapeutics Stock (OTCMKTS:ATRX)

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

ATRX Stock Price History

ATRX Stock News Headlines

January 30, 2024 | investing.com
Adhera Therapeutics Inc (ATRX)
August 24, 2023 | seekingalpha.com
ATRX Adhera Therapeutics, Inc.
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
May 22, 2023 | seekingalpha.com
Intensity Therapeutics upsizes proposed IPO to $15M from $8M
February 27, 2023 | finance.yahoo.com
Adhera Therapeutics, Inc. (ATRX)
January 25, 2023 | finance.yahoo.com
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
January 18, 2023 | seekingalpha.com
CGTX Cognition Therapeutics, Inc.
December 5, 2022 | seekingalpha.com
Adhera Therapeutics files for Nasdaq uplisting, $35M offering
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
October 9, 2022 | benzinga.com
Adhera Therapeutics Stock (OTC:ATRXD), Analyst Ratings, Price Targets, Predictions
September 21, 2022 | benzinga.com
Adhera Therapeutics Announces CEO, Senior...
September 19, 2022 | finance.yahoo.com
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
September 19, 2022 | seekingalpha.com
Adhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplist
July 19, 2022 | finance.yahoo.com
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin
May 19, 2022 | seekingalpha.com
Adhera Therapeutics appoints new Chairman of the Board, focuses on uplist to Nasdaq
May 19, 2022 | finance.yahoo.com
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
January 20, 2022 | finance.yahoo.com
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
November 22, 2021 | finance.yahoo.com
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders
November 8, 2021 | finance.yahoo.com
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors
October 20, 2021 | apnews.com
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary ...
October 20, 2021 | finance.yahoo.com
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications
October 16, 2021 | apnews.com
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s ...
October 15, 2021 | finance.yahoo.com
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease
October 4, 2021 | finance.yahoo.com
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
September 15, 2021 | insidermonkey.com
5 Penny Stocks with Upcoming Growth Catalysts
September 13, 2021 | apnews.com
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease ...
September 13, 2021 | finance.yahoo.com
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs
See More Headlines
Receive ATRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ATRX
CUSIP
N/A
CIK
737207
Web
adherathera.com
Phone
919-518-3748
Fax
206-830-9424
Employees
2
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,110,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-5,805.73%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($7.02) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
11,630,000
Free Float
7,955,000
Market Cap
$69,780.00
Optionable
Not Optionable
Beta
-0.15
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Andrew Albert Kucharchuk M.B.A. (Age 43)
    Vice Chairman, COO, Acting CFO & Chief Business Officer
    Comp: $285k

Key Competitors

View All Competitors

ATRX Stock Analysis - Frequently Asked Questions

How have ATRX shares performed in 2024?

Adhera Therapeutics' stock was trading at $0.03 at the start of the year. Since then, ATRX stock has decreased by 80.0% and is now trading at $0.0060.
View the best growth stocks for 2024 here.

Are investors shorting Adhera Therapeutics?

Adhera Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 100 shares, a decrease of 95.0% from the February 29th total of 2,000 shares. Based on an average trading volume of 220,800 shares, the days-to-cover ratio is currently 0.0 days.
View Adhera Therapeutics' Short Interest.

When did Adhera Therapeutics' stock split?

Shares of Adhera Therapeutics reverse split on Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Adhera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

How do I buy shares of Adhera Therapeutics?

Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ATRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media